Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03243305 · ClinicalTrials.gov registry record · Phase 3
AMP002 Phase III Contraceptive Study
A Phase 3 study, sponsored by Evofem.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,384
- Enrollment target
NCT03243305: Completed Phase 3 study, sponsored by Evofem.
NCT03243305 is a Phase 3 study that has completed, run by Evofem. The registered enrollment target is 1,384 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03243305, a Phase 3 study, has completed, sponsored by Evofem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,384 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
Primary Outcome
To evaluate the contraceptive efficacy of Amphora over 7-cycle of use
Interventions
- DRUG AMPHORA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,384 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2018-11-29 |
| Phase | Phase 3 |
What the finished NCT03243305 record still lists
NCT03243305 is an interventional study that assigns participants to a tested intervention. Its 1,384 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% higher).
The record links to 0 conditions, and to 1 intervention - of which AMPHORA is the first listed.
NCT03243305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03243305 about?
NCT03243305 is a clinical study titled "AMP002 Phase III Contraceptive Study". This is a single-arm, open-label, Phase III study in approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
What is the current status of trial NCT03243305?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,384 participants. The study started on 2017-07-24. Estimated completion is 2018-11-29.
What interventions are being tested in trial NCT03243305?
The interventions under investigation include: AMPHORA (DRUG).
Who is sponsoring clinical trial NCT03243305?
This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03243305's enrollment target sits among peer trials
1,384 176th of 2000 higher than 1,825 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06651281 · 1,380 participants · Phase 3
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- NCT05006131 · 1,395 participants
Pancreatic Cancer Screening for At-risk Individuals
- NCT07256392 · 1,370 participants · Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI